In this AD mouse model, it has been shown that the treatment with JWH-133, a specific CB2 cannabinoid receptor agonist, induced cognitive improvement due to decreased microglial reactivity and reduced expression of pro-inflammatory cytokines IL-1β, IL-6, TNFα, and IFNγ [7]. This evidence concerns the gene IL6 and Alzheimer disease.